GH1 and metastatic neoplasm: Osteosarcoma mouse models exhibit reduction in metastatic disease and an 85% reduction in IGF-1 levels following removal of the pituitary gland, which suggests that IGF-1, as a downstream effector of growth hormone (GH), may be partially responsible for osteosarcoma proliferation [28].